Skip to content
MarketScale
‹ Back to IndustriesHealthcare

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

As most people know, unexpected visits to the doctor can lead to high medical bills. An estimated 1 out of every 5 Americans offset these costs by using a Health Savings Account or HSA to help them save for rainy days or simply to plan ahead. However, it wasn’t long ago that this now…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

As most people know, unexpected visits to the doctor can lead to high medical bills. An estimated 1 out of every 5 Americans offset these costs by using a Health Savings Account or HSA to help them save for rainy days or simply to plan ahead. However, it wasn’t long ago that this now common practice wasn’t possible because of preexisting privacy laws.

On an upcoming episode of I Don’t Care with Kevin Stevenson, Kevin sits down with the Founder and Vice Chairman of Health Equity, Steve Neeleman. Steve was once a doctor and an aspiring entrepreneur who envisioned a concept where you buy insurance for the large events and put the difference in a HSA savings account, which could be used for the “small stuff.”

But, he discovered that when the law establishing HIPPA was passed there was a component that aligned closely with his concept for a health savings account, however, it was limited to a group of small business owners.

With the idea of creating a company called Health Equity, He works between shifts at the hospital on refining and executing the plan, begins lining up investors and takes time off to travel to Washington DC. As a citizen and physician, he lobbies for the passage of legislation for health savings accounts for companies of all sizes.

This is how the idea for his company, Health Equity, was formed. Between shifts at the hospital, he worked to refine his business plan, lining up investors and taking time off to travel to Washington D.C. to lobby for the passage of legislation for health savings accounts for companies of all sizes.

How the COVID-19 Vaccine for Children Differs From Adults’

What is Behind the “Mergers & Acquisitions” Boom in Healthcare?

Should the COVID-19 Vaccine’s Intellectual Property Be Accessible for Everyone?

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512